Palvella Therapeutics(PVLA)
WAYNE, PA
BiotechnologyFocus: Small Molecules
Palvella Therapeutics is a life sciences company focused on Small Molecules.
Funding Stage
PUBLIC
Open Jobs
0
Pipeline & Clinical Trials
QTORIN 3.9% rapamycin anhydrous gel
Cutaneous Venous MalformationsClinical Trials (1)
NCT06653842A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations
Phase 2Phase 2
Clinical Trials (1)
NCT04893486CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of Basal Cell Carcinomas (BCCs) In Patients With Gorlin Syndrome
Phase 2Phase 2
Clinical Trials (1)
NCT05050149Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations
Phase 2PTX-022
Pachyonychia CongenitaClinical Trials (1)
NCT03920228Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita
Phase 2/3QTORIN 3.9% Rapamycin Anhydrous Gel
Microcystic Lymphatic MalformationClinical Trials (1)
NCT06239480SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations
Phase 3PTX-022
Pachyonychia CongenitaClinical Trials (1)
NCT04520750VALO-2: Study Evaluating the Safety and Efficacy of PTX022 in the Treatment of Adults With Pachyonychia Congenita
Phase 3QTORIN 3.9% rapamycin anhydrous gel
Pachyonychia CongenitaClinical Trials (1)
NCT05180708A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
Phase 3PTX-022
Pachyonychia CongenitaClinical Trials (1)
NCT05643872A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita
Phase 3Open Jobs (0)
No open positions listed yet. Check their careers page directly.
Interview Prep Quick Facts
Portfolio: 8 clinical trials
SEC Filings: 2 available